Form 4: Generation Bio Director Granted 30,000 Stock Options

Dannielle Appelhans, a Director at Generation Bio Co., was granted 30,000 stock options with an exercise price of $0.3874, aligning her interests with shareholders.

Summary

• Dannielle Appelhans, a Director of Generation Bio Co. (GBIO), was granted 30,000 stock options.
• The options have an exercise price of $0.3874 per share.
• The grant date for these options was June 4, 2025.
• The shares underlying the option will fully vest on the earlier of June 4, 2026, and the date of Generation Bio's 2026 annual meeting of stockholders.
• The options are set to expire on June 3, 2035.

Sentiment

Score: 7

Explanation: The sentiment is positive as it represents a standard and beneficial practice of aligning director incentives with shareholder interests, indicating stability in corporate governance and compensation.

Positives

• The grant of stock options to a director helps align management and director interests with those of shareholders, as the value of the options increases with the company's stock price.
• This is a standard form of compensation, indicating continued commitment and retention of key personnel.

Future Outlook

The vesting schedule indicates a future commitment period for the director, with options fully vesting by June 4, 2026, or the date of the 2026 annual meeting, aligning the director's long-term incentives with company performance.

Industry Context

The granting of stock options to directors is a common practice across various industries, particularly in biotechnology and growth-oriented companies, to incentivize long-term performance and align leadership interests with shareholder value creation.

Comparison to Industry Standards

• Granting stock options to non-executive directors is a standard compensation practice in the biotechnology and pharmaceutical sectors, similar to companies like Moderna or BioNTech, to attract and retain experienced board members.
• The vesting schedule, tied to a future date or annual meeting, is typical for director equity awards, ensuring continued engagement over a period.

Stakeholder Impact

• Shareholders: The grant of options can lead to potential future dilution if exercised, but it also aims to align the director's interests with shareholder value creation.
• Director (Dannielle Appelhans): Receives equity compensation, incentivizing her to contribute to the company's long-term success.

Next Steps

• The stock options will vest on the earlier of June 4, 2026, or the date of Generation Bio's 2026 annual meeting of stockholders.

Key Dates

Keywords

Generation Bio Co., GBIO, Stock Options, Director Compensation, SEC Form 4, Insider Transaction, Equity Compensation